Granted Patent
B2
US 12,385,909 · App. 17/962,125 · Granted Aug 12, 2025
System for detecting infection in synovial fluid
Inventors:
Carl Deirmengian (Newton Square, PA); Richard C. Birkmeyer (Landenberg, PA); Keith Kardos (Bethlehem, PA); Patrick Kilmartin (Rochester, NY); Alexander Cameron (Cherry Hill, NJ); Kevin Schiller (Phoenixville, PA); Eun Kyung Chung (Avondale, PA)
Assignee:
CD Diagnostics, Inc.
G01N33/54388G01N33/5748G01N33/6869G01N33/6893G01N2333/515G01N2333/535G01N2333/5412G01N2333/5421G01N2333/5428G01N2333/545G01N2333/7158G01N2333/72G01N2333/795G01N2333/966G01N2800/10G01N2800/26G01N2800/60G01N2800/7095
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.
Claims (9)
1. A system for diagnosing joint infection in a subject, wherein the system detects the presence of a biomarker for joint infection in synovial fluid obtained from the subject and in contact with a buffer to maintain a pH in a range of from about 5 to about 9, wherein detection of the biomarker diagnoses joint infection in the subject with at least 90% accuracy, wherein the biomarker is selected from the group consisting of IL-1α, HNP1-3, ELA-2, bacterial permeability increasing protein (BPI), neutrophil gelatinase-associated lipocalin (NGAL), Resistin, Thrombospondin, Lactoferrin, IL-1β, IL-8, C-reactive protein (CRP), TNFα, IL-6, HNE, a2M, vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), skin derived antileukoproteinase (SKALP), IP-10, leukocyte-derived matrix metalloproteinase (LMP), and Orsomucoid, and any combination thereof, wherein the system comprises:
a) a first region comprising a first detection reagent that detects the presence of the biomarker for joint infection in synovial fluid, wherein the first detector reagent specifically binds the biomarker,
b) a second region comprising an internal control detector reagent comprising aggrecan for verification of synovial fluid, wherein the internal control detector reagent specifically binds a marker of synovial fluid;
wherein joint infection is diagnosed when the biomarker and the marker of synovial fluid are detected and the first region and second region are in flow communication with each other.
2. The system of claim 1 , wherein the system is capable of diagnosing joint infection when the marker for synovial fluid is detected at a higher signal intensity than the biomarker, by the system.
3. The system of claim 1 , wherein the biomarker is IL-1α.
4. The system of claim 2 , wherein the marker of synovial fluid is selected from the group consisting of hyaluronic acid (HA), mucopolysaccharide, glucosamine, chondroitin sulfate cartilage oligomeric matrix protein, lumican, lubricin, and any combination thereof.
5. The system of claim 1 , wherein the system has a sensitivity and specificity of at least 90% for joint infection.
6. The system of claim 1 , wherein the joint is selected from the group consisting of a native joint and a replacement joint.
Continuity (4)
Continuation
14371965
Provisional Application
61590234
· Jan 24, 2012
References Cited (157)
US 4366241A
· Tom et al.
· 1982
[cited by applicant]
US 4376110A
· David et al.
· 1983
[cited by applicant]
US 4517288A
· Giegel et al.
· 1985
[cited by applicant]
US 4837168A
· De Jaeger et al.
· 1989
[cited by applicant]
US 5143854A
· Pirrung et al.
· 1992
[cited by applicant]
US 5550061A
· Stone
· 1996
[cited by applicant]
US 5800992A
· Fodor et al.
· 1998
[cited by applicant]
US 5837832A
· Chee et al.
· 1998
[cited by applicant]
US 5948692A
· Miyauti et al.
· 1999
[cited by applicant]
US 5953727A
· Maslyn et al.
· 1999
[cited by applicant]
US 5972594A
· Heine
· 1999
[cited by applicant]
US 6248598B1
· Bogema
· 2001
[cited by applicant]
US 6365352B1
· Yerramilli et al.
· 2002
[cited by applicant]
US 6433012B1
· Tuse et al.
· 2002
[cited by applicant]
US 6654120B2
· Ban
· 2003
[cited by applicant]
US 6716641B1
· Sundrehagen
· 2004
[cited by applicant]
US 7344893B2
· Kirkegaard et al.
· 2008
[cited by applicant]
US 7598080B2
· Deirmengian
· 2009
[cited by applicant]
US 20030077611A1
· Slepnev
· 2003
[cited by applicant]
US 20030082512A1
· Yerramilli et al.
· 2003
[cited by applicant]
US 20040175769A1
· Hara et al.
· 2004
[cited by applicant]
US 20050037344A1
· Stuhlmuller et al.
· 2005
[cited by applicant]
US 20050250141A1
· Lambert et al.
· 2005
[cited by applicant]
US 20060084096A1
· Boess et al.
· 2006
[cited by applicant]
US 20060240037A1
· Fey et al.
· 2006
[cited by applicant]
US 20060294604A1
· Fridman et al.
· 2006
[cited by applicant]
US 20090227692A1
· Li. et al.
· 2009
[cited by applicant]
US 20090291462A1
· Sumer
· 2009
[cited by examiner]
US 20090318301A1
· Deirmengian
· 2009
[cited by applicant]
US 20100061983A1
· Loetscher et al.
· 2010
[cited by applicant]
US 20100292154A1
· Millett
· 2010
[cited by examiner]
US 20100324146A1
· Fairley
· 2010
[cited by applicant]
US 20110218116A1
· Cook
· 2011
[cited by examiner]
US 20110244597A1
· Tsukada
· 2011
[cited by examiner]
US 20120010096A1
· Wohlgemuth et al.
· 2012
[cited by applicant]
CA 2862499A1
· 2013
[cited by applicant]
EP 0249418A2
· 1987
[cited by applicant]
EP 1310567A2
· 2003
[cited by applicant]
WO WO1993009668A1
· 1993
[cited by applicant]
WO WO1999032660A1
· 1999
[cited by applicant]
WO WO2010036930A1
· 2010
[cited by applicant]
WO WO2013112216A1
· 2013
[cited by applicant]
Farahat et al., Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis, Annals of the Rheumatic Diseases, 1993; 52; pp. 870-875. (Year: 1993).
[cited by examiner]
“U.S. Appl. No. 14/371,965, Advisory Action mailed Sep. 30, 2016”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Final Office Action mailed Apr. 19, 2018”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Final Office Action mailed Jun. 8, 2017”, 26 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Final C Office Action mailed Jul. 22, 2016”, 18 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Non Final Office Action mailed Jan. 20, 2016”, 19 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Non Final Office Action mailed Feb. 8, 2017”, 22 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Non Final Office Action mailed Dec. 18, 2017”, 20 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Notice of Allowance mailed Jun. 29, 2018”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Preliminary Amendment filed Oct. 27, 2014”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, PTO Response to Rule 312 Communication mailed Oct. 29, 2018”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Response filed Mar. 19, 2018 to Non Final Office Action mailed Dec. 18, 2017”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Response filed May 8, 2017 to Non Final Office Action mailed Feb. 8, 2017”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Response filed May 17, 2016 to Non Final Office Action mailed Jan. 20, 2016”, 18 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Response filed Jun. 18, 2018 to Final Office Action mailed Apr. 19, 2018”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Response filed Sep. 8, 2017 to Final Office Action mailed Jun. 8, 2017”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Response filed Sep. 23, 2016 to Final Office Action mailed Jul. 22, 2016”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Response filed Oct. 19, 2016 to Advisory Action mailed Sep. 30, 2016”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Response filed Oct. 31, 2015 to Restriction Requirement mailed Jun. 1, 2015”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 14/371,965, Restriction Requirement mailed Jun. 1, 2015”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Corrected Notice of Allowability mailed Jul. 27, 2022”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Examiner Interview Summary mailed Jul. 14, 2022”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Final Office Action mailed Apr. 11, 2022”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Final Office Action mailed Jul. 6, 2021”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Non Final Office Action mailed Jan. 11, 2021”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Non Final Office Action mailed Nov. 18, 2021”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Notice of Allowance mailed Jul. 20, 2022”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Response filed Feb. 17, 2022 to Non Final Office Action mailed Nov. 18, 2021”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Response filed Apr. 12, 2021 to Non Final Office Action mailed Jan. 11, 2021”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Response filed Jul. 8, 2022 to Final Office Action mailed Apr. 11, 2022”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Response filed Oct. 6, 2021 to Final Office Action mailed Jul. 6, 2021”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Response filed Oct. 19, 2020 to Restriction Requirement mailed Aug. 17, 2020”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Restriction Requirement mailed Aug. 17, 2020”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Supplemental Amendment filed Jul. 11, 2022”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/142,550, Supplemental Preliminary Amendment filed Nov. 12, 2018”, 6 pgs.
[cited by applicant]
“Application Serial No. 2012367247, Voluntary Amendment filed Sep. 15, 2014”, 14 pgs.
[cited by applicant]
“Australian Application Serial No. 2012367247, First Examiners Report mailed Oct. 3, 2017”, 5 pgs.
[cited by applicant]
“Australian Application Serial No. 2012367247, Response filed Feb. 23, 2018 to Subsequent Examiners Report mailed Dec. 21, 2017”, 9 pgs.
[cited by applicant]
“Australian Application Serial No. 2012367247, Response filed Dec. 6, 2017 to First Examiners Report mailed Oct. 3, 2017”, 9 pgs.
[cited by applicant]
“Australian Application Serial No. 2012367247, Subsequent Examiners Report mailed Dec. 21, 2017”, 4 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,862,499, Examiner's Rule 30(2) Requisition mailed Aug. 27, 2019”, 7 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,862,499, Office Action mailed Dec. 7, 2018”, 6 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,862,499, Response filed Feb. 26, 2020 to Examiner's Rule 30(2) Requisition mailed Aug. 27, 2019”, 16 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,862,499, Response filed May 30, 2019 to Office Action mailed Dec. 7, 2018”, 41 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,862,499, Voluntary Amendment filed Sep. 16, 2014”, 5 pgs.
[cited by applicant]
“European Application Serial No. 12866897.7, Communication Pursuant to Article 94(3) EPC mailed Aug. 10, 2017”, 4 pgs.
[cited by applicant]
“European Application Serial No. 12866897.7, Extended European Search Report mailed Dec. 7, 2015”, 10 pgs.
[cited by applicant]
“European Application Serial No. 12866897.7, Partial European Search Report mailed Aug. 14, 2015”, 7 pgs.
[cited by applicant]
“European Application Serial No. 12866897.7, Response filed May 17, 2017 to Action mailed Feb. 17, 2017”, 29 pgs.
[cited by applicant]
“European Application Serial No. 12866897.7, Response filed Jul. 11, 2016 to Extended European Search Report mailed Dec. 7, 2015”, 7 pgs.
[cited by applicant]
“European Application Serial No. 12866897.7, Response filed Dec. 8, 2017 to Communication Pursuant to Article 94(3) EPC mailed Aug. 10, 2017”, 11 pgs.
[cited by applicant]
“European Application Serial No. 18184143.8, Communication Pursuant to Article 94(3) EPC Oct. 9, 2019”, 6 pgs.
[cited by applicant]
“European Application Serial No. 18184143.8, Extended European Search Report mailed Sep. 6, 2018”, 7 pgs.
[cited by applicant]
“European Application Serial No. 18184143.8, Response filed Feb. 17, 2020 to Communication Pursuant to Article 94(3) EPC Oct. 9, 2019”, 129 pgs.
[cited by applicant]
“European Application Serial No. 18184143.8, Response filed Jun. 26, 2019 to Extended European Search Report mailed Sep. 6, 2018”, 14 pgs.
[cited by applicant]
“Gene Characterization Kits”, Stratagene Catalog, (1988), 39 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2012/061350, International Preliminary Report on Patentability mailed Aug. 7, 2014”, 8 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2012/061350, International Search Report mailed Mar. 12, 2013”, 4 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2012/061350, Invitation to Pay Additional Fees mailed Jan. 9, 2013”, 2 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2012/061350, Written Opinion mailed Mar. 12, 2013”, 6 pgs.
[cited by applicant]
Akobeng, Anthony K., “Understanding diagnostic tests 3: receiver operating characteristic curves”, Acta Pædiatrica ISSN 0803-5253; 96, (2007), pp. 644-647.
[cited by applicant]
Altschul, “A Protein Alignment Scoring System Sensitive at all Evolutionary Distances”, J. Mol. Evol., vol. 36, (1993), 290-300.
[cited by applicant]
Altschul, et al., “Issues in Searching Molecular Sequence Databases”, Nature Genet., vol. 6, (1994), 119-129.
[cited by applicant]
Baker, “In Biomarkers We Trust”, Nature Biotechnology, (2005), 297-304.
[cited by applicant]
Barnes, M G, et al., “Gene Expression in Juvenile Arthritis and Spondyloarthropathy: Pro-angiogenic ELR+ Chemokine Genes Relate to Course of Arthritis”, Rheumatology, vol. 43, No. 8, (2004), 973-979.
[cited by applicant]
Bast, et al., “Translational Crossroads for Biomarkers”, Clin Cancer Res, (2005), 6103-6108.
[cited by applicant]
Bohunicky, B, et al., “Biosensors: The New Wave in Cancer Diagnosis”, Nanotechnology Science and Applications, vol. 4, No. 1, (2011), 1-10.
[cited by applicant]
Bokarewa, Maria I., et al., “Intraarticular Release and Accumulation of Defensins and Bactericidal/Permeability-Increasing Protein in Patients With Rheumatoid Arthritis”, Journal of Rheumatology, vol. 30, No. 8; XP05539…
[cited by applicant]
Buck, C, et al., “Interleukin-6: A Sensitive Parameter for the Early Diagnosis of Neonatal Bacterial Infection”, Pediatrics, vol. 93(1), (1994), 54-58.
[cited by applicant]
Caramia, et al., “Acute bone and joint infections in children and therapeutic options”, Journal of Pediatric Infectious Diseases 2, (2007), 193-203.
[cited by applicant]
Dagleish, et al., “A Preliminary Evaluation of the Use of Equine Neutrophil Elastase 2A Concentration in Synovial Fluid as a Marker for Joint Inflammation in Horses”, Equine Veterinary Journal, Equine vet. J. (2003) 35 …
[cited by applicant]
Deirmengian, C, et al., “Synovial Fluid Biomarkers for Periprosthetic Infection”, Clin Orthop Relat Res.; 2017-2023 pgs, (Mar. 19, 2010), 7 pgs.
[cited by applicant]
Deirmengian, C, et al., “The Mark Coventry Award: White Blood Cell Gene Expression: A New Approach Toward the Study and Diagnosis of Infection”, Clin. Orthop. Relal. Res., vol. 440, (2005), 38-44.
[cited by applicant]
Elsaid, et al., “Decreased Lubricin Concentrations and Markers of Joint Inflammation in the Synovial Fluid of Patients With Anterior Cruciate Ligament Injury”, Arthritis & Rheumatism, vol. 58, No. 6, (Jun. 2008), 1707-1…
[cited by applicant]
Fink, et al., “The value of synovial biopsy, joint aspiration and C-reactive protein in the diagnosis of late peri-prosthetic infection of total knee replacements”, The Journal of Bone and Joint Surgery. British vol. vo…
[cited by applicant]
Friese, M A, et al., “Release of Endogenous Anti-Inflammatory Complement Regulators FHL-1 and Factor H Protects Synovial Fibroblasts during Rheumatoid Arthritis”, Clin. Exp. Immunol., vol. 132, No. 3, (2003), 485-495.
[cited by applicant]
Golub, T. R., et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”, Science, vol. 286, (Oct. 15, 1999), 531-537.
[cited by applicant]
Greenbaum, D, et al., “Comparing protein abundance and mRNA expression levels on a genomic scale”, Genome Biology 4:, (2003), 117.
[cited by applicant]
Harada, A, et al., “Essential involvement of interleuikin-8 (IL-8) in acute inflammation”, Journal of Leukocyte Biology, vol. 56, (1994), 559-564.
[cited by applicant]
Heller, Renu A., et al., “Discovery and analysis of inflammatory disease-related genes using cDNA microarrays”, Proc. Natl. Acad. Sci. USA, vol. 94, (Mar. 1997), 2150-2155.
[cited by applicant]
Henikoff, et al., “Amino Acid Substitute Matrices from Protein Blocks”, Proc. Natl. Acad. Sci. USA, vol. 89, (1992), 10915-10919.
[cited by applicant]
Hii, et al., “Regulation of Human Neutrophil-mediated Cartilage Proteoglycan Degradation by Phosphatidylinositol-3-kinase”, Immunology, vol. 102(1), (2001), 59-66.
[cited by applicant]
Huse, et al., “Generation of Large Combination Library of the Immunoglobulin Repertoire in Phage Lambda”, Science, vol. 246, (1989), 1275-1281.
[cited by applicant]
Jacovides, Christina L., et al., “Molecular Markers for Diagnosis of Periprosthetic Joint Infection”, The Journal of Arthroplasty, Churchill Livingstone, Amsterdam, NL, vol. 26, No. 6, XP028280934, ISSN: 0883-5403, DOI:…
[cited by applicant]
Jungblut, et al., “Protein Identification from 2-DE gels by MALDI Mass Spectrometry”, Mass Spectr. Rev., vol. 16, (1997), 145-162.
[cited by applicant]
Karlin, S., et al., “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes.”, Proc Natl Acad Sci U S A., 87(6), (Mar. 1990), 2264-8.
[cited by applicant]
Kleesiek, et al., “Granulocyte Elastase as a New Biochemical Marker in the Diagnosis of Chronic Joint Diseases”, Rheumatol Int 6, (1986), 161-169.
[cited by applicant]
Kohler, G., et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”, Nature, 256(5517), (1975), 495-497.
[cited by applicant]
Labaer, et al., “So you want to look for biomarkers”, Journal of Proteome Research, (2005), 1053-1059.
[cited by applicant]
Lockhart, D. J., et al., “Expression monitoring by hybridization to high-density oligonucleotide arrays”, Nature Biotechnology, 14 (13), (Dec. 1996), 1675-1680.
[cited by applicant]
Martins, “Development of Internal Controls for the luminex instrument as part of a multiplex seven-analyte viral respiratory antibody profile”, Clinical and Diagnostic laboratory Immunolog, (2002), 41-45.
[cited by applicant]
McGall, G., et al., “Light-Directed synthesis of high-density oligonucleotide arrays using semiconductor photoresists”, PNAS, 93, (Nov. 1996), pp. 13555-13460.
[cited by applicant]
O'Hara, R, et al., “Local Expression of the Serum Amyloid A and Formyl Peptide Receptor-like 1 Genes in Synovial Tissue is Associated with Matrix Melalloproleinase Production in Patients with Inflammatory Arthritis”, Ar…
[cited by applicant]
Paulsen, et al., “Detection of Antimicrobial peptides in human osteoarthritic cartilage and synovial membrane”, Poster Session—Osteoarthritis—Hall E 47th Annual Meeting, Orthopaedic Research Society, San Francisco, Cali…
[cited by applicant]
Paulsen, Friedrich, et al., “Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes”, Journal of Pathology, John Wiley & Sons Ltd, GB, vol. 198, No. 3, XP008115110, ISSN: 0022…
[cited by applicant]
Pufe, T, et al., “Expression of Pleiotrophin, an Embryonic Growth and Differentiation Factor, in Rheumatoid Arthritis”, Arthritis Rheum., vol. 48, No. 3, (2003), 660-667.
[cited by applicant]
Riepl, Birgit, et al., “Tumor necrosis factor and norepinephrine lower the levels of human neutrophil peptides 1-3 secretion by mixed synovial tissue cultures in osteoarthritis and rheumatoid arthritis”, Arthritis Resea…
[cited by applicant]
Stuhlmuller, B, et al., “Identification of Known and Novel Genes in Activated Monocytes from Patients with Rheumatoid Arthritis”, Arthritis Rheum., vol. 43, No. 4, (2000), 775-790.
[cited by applicant]
Torzewski, et al., “Animal Models of C-Reactive Protein”, Hindawi Publishing Corporation, Mediators of Inflammation, vol. Article ID 683598,, (2014), 1-7.
[cited by applicant]
Van Der Vekiens, Nicky, et al., “Human and equine cardiovascular endocrinology: beware to compare”, Cardiovascular Endocrinology, vol. 2, No. 4, (2013), 67-76.
[cited by applicant]
Varoga, et al., “The antimicrobial peptide HBD-2 and the Toll-like receptors-2 and -4 are induced in synovial membranes in case of septic arthritis”, Virchows Arch, (2009), 685-694.
[cited by applicant]
Ward, E. Sally, et al., “Binding activities of a repertoire of single-immunoglobulin variable domains secreted from
[cited by applicant]
Yerramilli, S, et al., “RNA Expression Patterns Change Dramatically in Human Neutrophils Exposed to Bacteria”, Blood, vol. 97, No. 8, (2001), 2457-2468.
[cited by applicant]
Yum, et al., “Involvement of Phosphoinositide 3-Kinases in Neutrophil Activation and the Development of Acute Lung Injury”, J. Immunology, vol. 161, (2001), 6601-6608.
[cited by applicant]
Zanders, E D, et al., “Analysis of Immune System Gene Expression in Small Rheumatoid Arthritis Biopsies Using a Combination of Subtractive Hybridization and High-Density eDNA Arrays”, J. Immunol, Methods, vol. 233, No. …
[cited by applicant]
U.S. Appl. No. 14/371,965 U.S. Pat. No. 10,139,405, filed Jul. 11, 2014, System for Detecting Infection in Synovial Fluid.
[cited by applicant]
U.S. Appl. No. 16/142,550, filed Sep. 26, 2018, System for Detecting Infection in Synovial Fluid.
[cited by applicant]